TG Therapeutics Q3 EPS beats estimate, sales beat; raises full-year revenue guidance

TG Therapeutics reported Q3 2026 EPS of $0.35, beating the $0.34 estimate, on sales of $259.936M that beat the $245.475M estimate. Management said it is on track to exceed $1 billion in global revenue for the full year.

Detected & updated continuously · Source: Nebula